Panoptica Inc., of Bernardsville, N.J., said it secured $11 million in a series B financing. The additional financing, provided by Third Rock Ventures and SV Health Investors (formerly SV Life Sciences), will enable clinical advancement of PAN-90806, a small-molecule anti-vascular endothelial growth factor (anti-VEGF) eye drop for the treatment of neovascular eye diseases.